4507-57-7

Basic information

• Product Name: Methyl-1-aminocyclohexane carboxylate (free base)
• Synonyms: Methyl-1-aminocyclohexane carboxylate (free base);METHYL1-AMINOCYCLOHEXANECARBOXYLATE;Methyl 1-Aminocyclohexanate;Methyl-1-aminocyclohexane carboxylat;Methyl 1-Aminocyclohexanoate;2-aMino-2-Methylcyclohexane-1-carboxylate;cyclohexanecarboxylic acid, 1-aMino-, Methyl ester
• CAS NO: 4507-57-7
• Molecular Formula: C₈H₁₅NO₂
• Molecular Weight: 157.21
• Product Categories: Amino Acids and Derivatives;Cycloalkanes
• Mol File: 4507-57-7.mol

Chemical Properties

• Boiling Point: 209.9°C at 760 mmHg
• Flash Point: 79.4°C
• Appearance: /
• Density: 1.047g/cm³
• Vapor Pressure: 0.198mmHg at 25°C
• Refractive Index: 1.472
• Storage Temp.: 2-8°C(protect from light)
• PKA: 7.19±0.70(Predicted)
• CAS DataBase Reference: Methyl-1-aminocyclohexane carboxylate (free base)(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl-1-aminocyclohexane carboxylate (free base)(4507-57-7)
• EPA Substance Registry System: Methyl-1-aminocyclohexane carboxylate (free base)(4507-57-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 4507-57-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl-1-aminocyclohexane carboxylate (free base) is used as a precursor or intermediate in the synthesis of various pharmaceuticals and organic compounds, leveraging its unique chemical structure to contribute to the development of new medications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Methyl-1-aminocyclohexane carboxylate (free base) is utilized as a key component in the design and synthesis of drugs targeting the central nervous system, due to its ability to modulate neurotransmitter activity.
Used in Drug Development:
Methyl-1-aminocyclohexane carboxylate (free base) is employed in drug development for its potential to influence neurotransmitter levels and activity, which can be crucial in the treatment of neurological disorders and conditions related to neurotransmission imbalances.

InChI:InChI=1/C8H15NO2/c1-11-7(10)8(9)5-3-2-4-6-8/h2-6,9H2,1H3

Upstream product

• 702-62-5 spiro(imidazolidine-4,1'-cyclohexane)-2,5-dione 
• 813452-54-9 C₂₃H₂₅NO₄ 
• 217299-03-1 4-aminotetrahydro-2H-pyran-4-carboxylic acid hydrochloride 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 2756-85-6 1-aminocyclohexane carboxylic acid 
• 108-94-1 cyclohexanone 

Downstream Products

• 144876-59-5 methyl 1-isocyanato-1-cyclohexanecarboxylate 
• 797798-56-2 1-(3-Cyclohexyl-ureido)-cyclohexanecarboxylic acid methyl ester 
• 707-09-5 3-Methyl-5,5-pentamethylen-hydantoin 
• 306768-96-7 (2S)-1-[3-(1-t-butoxycarbonyl-3-methylbutyl)ureido]cyclohexane-1-carboxylic acid methyl ester 
• 847665-26-3 4-{1-[(1-(methoxycarbonyl)cyclohexylcarbamoyl)methyl]-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-ylmethyl}-imidazole-1-carboxylic acid tert-butyl ester 
• 1001423-22-8 6-(2-chlorophenyl)-7-(4-trifluoromethylphenyl)-3-[N-(1-methoxy-carbonylcyclohexyl)-sulfamoyl]-2-methylpyrazolo[1,5-a]pyrimidine 
• 256477-68-6 methyl 1-{[(1,4-dichloro-7-isoquinolinyl)sulphonyl]amino}cyclohexanecarboxylate 
• 946860-51-1 C₁₅H₂₅NO₃ 
• 946860-53-3 C₁₅H₁₇F₂NO₃ 
• 256478-54-3 methyl 1-{[(4-chloro-1-guanidino-7-isoquinolinyl)sulphonyl]amino}cyclohexanecarboxylate 

Relevant articles and documents

PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula (I), wherein the variables Q and R1 and R2 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

SUBSTITUTED PYRIDOXAZINES

The invention provides compounds having the structure of formula I, and prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof, wherein A, Y and the groups R1, R2, R

Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups

Optimization of the amino acid residue within a series of anthranilimide-based glycogen phosphorylase inhibitors is described. These studies culminated in the identification of anthranilimides 16 and 22 which displayed potent in vitro inhibition of GPa in

A PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND

The present invention provides a pyrazolo[1,5-a]pyrimidine compound, having CB1 receptor-antagonizing activity, of the following formula [I]: in which R1 and R2 are the same or different and each an optionally substituted aryl group etc, R0 is hydrogen atom, an alkyl group etc, E is a group of the formula: -C(=O)- or -SO?2#191-, R is a group of the following formula [i], [ii] or [iii] etc: Ring A is (a) a C?3-8#191 cycloalkyl group optionally fused to a benzene ring or (b) a benzene ring, Q is a single bond or a methylene group, Ring B is a 4- to 7-membered aliphatic heterocyclic group, said cyclic group binding via its ring-carbon atom to the adjacent nitrogen atom, X is sulfur atom etc, R3 is an alkyl group optionally substituted by an alkylthio group, R4 is hydrogen atom, an alkyl group etc, one of RA and RB is an alkyl group etc, and the other is hydrogen atom, an alkyl group etc, or a pharmaceutically acceptable salt thereof.

PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY

The present invention relates to a pyrazole compound having potent CB1-antagonizing activity, having the following formula [I]: wherein R1 and R2 are the same or different and an optionally substituted aryl group etc., R3 is an alkyl group etc., E is one of the following groups of the formula (i) to (iv): Q1 is a single bond, an alkylene group or a group of the formula: -N(R7)-, R7 is a hydrogen atom or an alkyl group, Q2 is a single bond, an oxygen atom or an alkylene group, R4 is a cycloalkyl group, a group of the formula: -N(R5)(R6) etc., one of R5 and R6 is a hydrogen atom or an alkyl group and the other is an alkyl group, a group of the formula: -N(R8)(R9) etc., D is an oxygen atom etc., RA1 is an amino group etc., RA2 is an optionally substituted aliphatic heterocyclic group, R is an alkyl group optionally substituted by one to three halogen atom(s) etc., one of R8 and R9 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., or a pharmaceutically acceptable salt thereof.

Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations formed therefrom

The present invention relates to spiroimidazolidine derivatives of the formula I in which E, V, W, X, R1and R2have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, such as, for example, rheumatoid arthritis, or allergic disorders. The compounds of the formula I are also inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy and prophylaxis of illnesses which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part. The invention also relates to processes for the preparation of the compounds of the formula I, pharmaceutical preparations which contain compounds of the formula I, and methods for treating these disorders.

Microbicidal compositions

1-Aminocyclohexanecarboxylic acid derivatives of the formula I STR1 or their acid addition salts or a metal complex can be employed for protecting plants from microorganisms. In the formula I, R1 is hydrogen or C1 -C4 alky